Existing investor Lilly Asia Ventures helped the genome editing technology developer push its overall funding past the $100m mark.

The Omron-backed disease prevention platform developer hiked its total debt and equity financing to $100m, King River Capital leading the series C.

The multicorporate-backed corporate venturing vehicle for online food wholesaler Oisix Ra Daichi has secured chemicals producer Fuso as an LP.

MIT's cancer drug developer Kronos Bio floated above its range in an upsized offering and saw its shares soar in price post-IPO.

Galecto has filed to go public nine years after being founded in Sweden to commercialise research from Lund and Edinburgh universities.

GV-backed cancer drug developer Kronos Bio floated above its range in an upsized offering and saw its shares soar in price post-IPO.

Tigermed took part in a round that will support clinical progression of a 3D Medicines product pipeline that includes oncology candidate envafolimab.

Merck Group, Bristol Myers-Squibb and Novo-backed cancer drug developer Galecto has filed to go public weeks after it last funding round.

Novo remains the largest shareholder in the endocrine disorder drug developer, which went public in an upsized offering.

Relx and Telus-backed TigerConnect has now raised $149m in equity and debt financing for its healthcare messaging and collaboration platform.